Medazepam is a DEA Schedule IV controlled substance. Substances in the DEA Schedule IV have a low potential for abuse relative to substances in Schedule III. It is a Depressants substance. MEDAZEPAM is a small molecule drug with a maximum clinical trial phase of IV and is indicated in anxiety. It is grouped under the following drug class(es): Anxiolytics, Benzodiazepines and Schedule IV controlled substances. Its therapeutic use is listed as antianxiety drugs. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Pamnace, Nobrium, Resmit, Rudotel and Enobrin. It is listed as a controlled drug substance (Schedule IV). Its PubChem CID is 4041.
Medazepam
| CAS No | 2898-12-6 |
|---|---|
| Molecular Formula | C16H15ClN2 |
| Molecular Weight | 270.75 g/mol |
| Synonyms | 7-chloro-1-methyl-5-phenyl-2,3-dihydro-1,4-benzodiazepine |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Medazepam is a DEA Schedule IV controlled substance. Substances in the DEA Schedule IV have a low potential for abuse relative to substances in Schedule III. It is a Depressants substance.
The listed CAS number is 2898-12-6.
The listed molecular formula is C16H15ClN2.
The listed molecular weight is 270.75 g/mol.
7-chloro-1-methyl-5-phenyl-2,3-dihydro-1,4-benzodiazepine.
The source lists Pamnace, Nobrium, Resmit, Rudotel and Enobrin.